Lantheus Holdings, Inc. (LNTH) Stock
1 member of Congress disclosed 4 trades in LNTH since 2025: 4 purchases and 0 sales, most recently Gilbert Cisneros (purchase, Jan 28, 2025). 6 of the hedge funds AlphaScala tracks reported LNTH in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $152.71M.
Which members of Congress traded Lantheus Holdings, Inc. (LNTH)?
Most recent: Gilbert Cisneros (purchase, Jan 28, 2025); records start Jan 7, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2025-01-28 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-01-13 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-01-08 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-01-07 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all LNTH political trades →Which hedge funds own LNTH?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.38M | $152.71M | +384% |
| Marshall Wace | 774K | $85.87M | +27% |
| Point72 Steve Cohen | 630K | $69.87M | -35% |
| Millennium Management Israel Englander | 336K | $37.32M | +32% |
| Bridgewater Associates Ray Dalio | 66K | $7.32M | +51% |
| D.E. Shaw David Shaw | 10K | $1.07M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →LNTH price chart
Powered by TradingViewWhat does Lantheus Holdings, Inc. do?
Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to assist clinicians in diagnosing and treating heart disease, cancer, and other conditions worldwide. Its portfolio includes DEFINITY, an injectable ultrasound enhancing agent for echocardiography; TechneLite, a technetium generator for nuclear medicine; Cardiolite for assessing heart muscle blood flow; PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent for prostate cancer lesions; Neurolite for stroke imaging; Xenon-133 for pulmonary function; and RELISTOR for opioid-induced constipation. The company also offers innovative AI-enabled solutions like PYLARIFY AI for quantitative PSMA PET/CT assessment, aPROMISE, Automated Bone Scan Index, and recent additions such as Flyrcado for heart blood flow evaluation, alongside expansions into Alzheimer's diagnostics through targeted radiodiagnostics. Lantheus Holdings, Inc. emphasizes precision medicine via strategic partnerships and biomarkers, serving oncology, cardiology, neurology, and non-oncologic sectors to enable clinicians to Find, Fight, and Follow disease. Founded in 1956 and headquartered in Billerica, Massachusetts, it plays a pivotal role in advancing radiopharmaceutical innovations.